Maxim Biomedical, Inc.


Maxim Biomedical (MaximBio) is a leading healthcare diagnostic company founded in 2005, dedicated to developing and manufacturing affordable, accessible diagnostic solutions to improve patient outcomes worldwide. The company specializes in lateral flow and diagnostic devices, with a focus on in vitro diagnostic (IVD) medical device systems. They serve industries including wellness, biodefense, veterinary, food safety, infectious disease, and women’s health care, with technologies found in over 60 diagnostic tests and more than 15 million tests produced globally. MaximBio emphasizes quality, innovation, and collaboration, partnering with healthcare companies and government agencies to bring new diagnostic products to market.

Industries

biotechnology
health-care
professional-services

Nr. of Employees

small (1-50)

Maxim Biomedical, Inc.

Rockville, Maryland, United States, North America


Products

COVID-19 antigen home test (EUA-authorized antigen test)

An over-the-counter antigen test for SARS-CoV-2 intended for at-home use under Emergency Use Authorization.

HIV-1 LAg-Avidity DBS ELISA kit (research use)

A dried blood spot (DBS) limiting antigen avidity ELISA intended for surveillance and incidence estimation (research use only).

HIV-1 Limiting Antigen (LAg) Avidity EIA Kit

An in-vitro quantitative limiting antigen avidity enzyme immunoassay for distinguishing recent HIV-1 infections from long-term infections, designed for surveillance purposes.

HIV-1 Limiting Antigen (LAg) Avidity DBS EIA Kit

Testing product for HIV screening, surveillance, diagnosis, and confirmation using dried blood spot (DBS).

Contract Assay Development

End-to-end diagnostic development services, tailored to support every stage of your IVD journey with a focus on quality, scalability, and regulatory readiness.

Contract Manufacturing Services

End-to-end manufacturing capabilities for lateral flow and ELISA diagnostics, providing flexible production from pilot batches to millions of units per month.


Services

End-to-end development from concept and prototyping through scale-up, verification/validation, and commercial production for IVD devices.

Formulation, preparation, and semi-automated/automated filling of buffer and reagent batches up to 1,000 L with cleanroom filling capability.

Automated assembly of devices and kits, kitting, packaging, labeling, and logistics support for commercial distribution.

Quality system implementation and regulatory support aligned with ISO 13485, FDA cGMP registration, CFR820 compliance, and device submission processes.

Conducting and documenting stability studies to support expiration dating and regulatory submissions for shelf-life extensions.

Expertise Areas

  • Lateral flow assay development and manufacturing
  • Point-of-care and over-the-counter diagnostic development
  • IVD assay development (LFA and ELISA)
  • Assay scale-up and GMP manufacturing
  • Show More (4)

Key Technologies

  • Lateral flow immunoassays (LFA)
  • Enzyme-linked immunosorbent assay (ELISA)
  • Multiplex immunoassays
  • Visual and fluorescent labeling
  • Show More (6)

News & Updates

MaximBio received a second NIH RADx Tech High Performance Award for the development of at-home FiarFly™ Reader and COVID-19 & Flu A/B Rapid Test.

MaximBio announced a $49.5 million award from the U.S. Department of Health and Human Services to strengthen pandemic testing efforts.

On October 26, 2023, the FDA extended the shelf-life of all ClearDetect™ COVID-19 tests to 24 months.

MaximBio received Emergency Use Authorization for their COVID-19 antigen home test.

MaximBio announced plans to produce millions of point-of-care COVID-19 tests delivering results in 15 minutes.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.